Candriam Luxembourg S.C.A. boosted its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 86.6% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 461,000 shares of the company’s stock after buying an additional 214,000 shares during the period. Candriam Luxembourg S.C.A. owned 0.52% of Neurocrine Biosciences worth $21,207,000 as of its most recent filing with the SEC.
Several other institutional investors also recently modified their holdings of the company. Dimensional Fund Advisors LP raised its position in Neurocrine Biosciences by 2.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 165,953 shares of the company’s stock valued at $6,422,000 after buying an additional 4,428 shares in the last quarter. Teachers Advisors LLC raised its position in Neurocrine Biosciences by 6.3% in the fourth quarter. Teachers Advisors LLC now owns 78,287 shares of the company’s stock valued at $3,030,000 after buying an additional 4,668 shares in the last quarter. Capstone Asset Management Co. acquired a new position in Neurocrine Biosciences during the first quarter valued at $214,000. Quantitative Systematic Strategies LLC purchased a new stake in Neurocrine Biosciences during the first quarter valued at about $261,000. Finally, Columbus Circle Investors increased its stake in Neurocrine Biosciences by 33.3% in the first quarter. Columbus Circle Investors now owns 207,699 shares of the company’s stock valued at $8,993,000 after buying an additional 51,872 shares in the last quarter. 95.87% of the stock is owned by institutional investors and hedge funds.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) traded down 0.48% during mid-day trading on Monday, hitting $53.81. 624,787 shares of the stock were exchanged. The company has a 50-day moving average of $48.53 and a 200-day moving average of $46.79. The stock’s market capitalization is $4.75 billion. Neurocrine Biosciences, Inc. has a 52 week low of $37.35 and a 52 week high of $55.38.
Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings results on Thursday, August 3rd. The company reported ($0.68) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.67) by $0.01. The business had revenue of $6.34 million for the quarter, compared to the consensus estimate of $0.61 million. During the same quarter in the prior year, the company earned ($0.46) EPS. On average, equities analysts predict that Neurocrine Biosciences, Inc. will post ($2.45) EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Position Increased by Candriam Luxembourg S.C.A.” was originally posted by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright laws. The legal version of this article can be read at https://stocknewstimes.com/2017/08/14/candriam-luxembourg-s-c-a-has-21-21-million-stake-in-neurocrine-biosciences-inc-nasdaqnbix-updated.html.
A number of brokerages have weighed in on NBIX. Cowen and Company reissued an “outperform” rating and set a $65.00 price target (up previously from $60.00) on shares of Neurocrine Biosciences in a research report on Wednesday, August 9th. Piper Jaffray Companies set a $68.00 price target on shares of Neurocrine Biosciences and gave the company a “buy” rating in a research report on Wednesday, May 24th. BidaskClub raised shares of Neurocrine Biosciences from a “hold” rating to a “buy” rating in a research report on Wednesday, August 9th. BMO Capital Markets raised their price target on shares of Neurocrine Biosciences from $75.00 to $84.00 and gave the company an “outperform” rating in a research report on Friday, August 4th. Finally, Oppenheimer Holdings, Inc. set a $70.00 price objective on shares of Neurocrine Biosciences and gave the company a “buy” rating in a research note on Wednesday, May 24th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and seventeen have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $68.25.
In other Neurocrine Biosciences news, insider Malcolm Lloyd-Smith sold 9,960 shares of the stock in a transaction that occurred on Friday, May 19th. The shares were sold at an average price of $53.63, for a total value of $534,154.80. Following the transaction, the insider now directly owns 17,997 shares in the company, valued at $965,179.11. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Christopher Flint Obrien sold 8,734 shares of the stock in a transaction that occurred on Thursday, July 27th. The shares were sold at an average price of $50.00, for a total transaction of $436,700.00. Following the completion of the transaction, the insider now owns 57,707 shares in the company, valued at $2,885,350. The disclosure for this sale can be found here. Insiders sold 66,548 shares of company stock worth $3,474,225 over the last quarter. 4.80% of the stock is currently owned by insiders.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
